IEQ Capital’s Ocular Therapeutix OCUL Stock Holding History

IEQ Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Sell	11,897 -635	-5%	-$5.76K	﹤0.01%	1916
2026 Q1	$106K	Hold	12,532	–	–	﹤0.01%	1792
2025 Q4	$152K	Hold	12,532	–	–	﹤0.01%	1731
2025 Q3	$146K	Hold	12,532	–	–	﹤0.01%	1728
2025 Q2	$116K	Sell	12,532 -5,097	-29%	-$39.9K	﹤0.01%	1700
2025 Q1	$129K	Hold	17,629	–	–	﹤0.01%	1443
2024 Q4	$151K	Hold	17,629	–	–	﹤0.01%	1239
2024 Q3	$153K	Hold	17,629	–	–	﹤0.01%	1080
2024 Q2	$121K	Sell	17,629 -12,500	-41%	-$77.2K	﹤0.01%	945
2024 Q1	$274K	Hold	30,129	–	–	﹤0.01%	792
2023 Q4	$134K	Sell	30,129 -54,400	-64%	-$161K	﹤0.01%	870
2023 Q3	$265K	Hold	84,529	–	–	0.01%	760
2023 Q2	$436K	Hold	84,529	–	–	0.01%	578
2023 Q1	$445K	Sell	84,529 -55,000	-39%	-$261K	0.01%	610
2022 Q4	$392K	Sell	139,529 -144,404	-51%	-$478K	0.01%	563
2022 Q3	$1.18M	Hold	283,933	–	–	0.03%	328
2022 Q2	$1.14M	Sell	283,933 -124,000	-30%	-$468K	0.03%	288
2022 Q1	$2.02M	Hold	407,933	–	–	0.05%	206
2021 Q4	$2.84M	Sell	407,933 -221,049	-35%	-$1.72M	0.07%	155
2021 Q3	$6.29M	Buy	628,982 +49	+0%	+$550	0.17%	79
2021 Q2	$8.92M	Hold	628,933	–	–	0.26%	58
2021 Q1	$10.3M	Hold	628,933	–	–	0.43%	42
2020 Q4	$13M	Sell	628,933 -50,300	-7%	-$747K	0.58%	40
2020 Q3	$5.17M	Hold	679,233	–	–	0.28%	60
2020 Q2	$5.66M	Buy	679,233 +423,188	+165%	+$2.81M	0.37%	47
2020 Q1	$1.27M	Hold	256,045	–	–	0.1%	122
2019 Q4	$1.01M	Buy	+256,045	New	+$890K	0.09%	155

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IEQ Capital's OCUL Position: Q2 2026 in Review

IEQ Capital reduced its Ocular Therapeutix (OCUL) stake by 5.1% in Q2 2026, selling an estimated $5.76K and leaving 11,897 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

IEQ Capital first reported a position in OCUL in Q4 2019 and has held it in 27 quarters since. The position peaked at $13M in Q4 2020. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

IEQ Capital held 11,897 shares of Ocular Therapeutix worth $117K as of Q2 2026.
IEQ Capital sold 635 Ocular Therapeutix shares in Q2 2026, an estimated $5.76K.
Ocular Therapeutix made up ﹤0.01% of IEQ Capital's portfolio in Q2 2026, its #1916 holding.
IEQ Capital first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 27 quarters since.
IEQ Capital's Ocular Therapeutix position peaked at $13M in Q4 2020.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.